Exax Inc. completed the acquisition of an additional 7.32% stake in Immunomic Therapeutics, Inc. from Wise Alliance Co.,Ltd., Benoholdings, Inc., Bellum 1 Fund and Ji-Man Park.
September 03, 2021
Share
exax Inc. (KOSDAQ:A060230) agreed to acquire an additional 7.32% stake in Immunomic Therapeutics, Inc. from Wise Alliance Co.,Ltd., Benoholdings, Inc. (KOSDAQ:A206400), Bellum 1 Fund and Ji-Man Park for KRW 12.4 billion on August 18, 2021. Under the terms of the transaction, exax Inc. will acquire an additional 2 million shares. Immunomic Therapeutics, Inc. had total assets of KRW 64.4 billon, total equity of KRW 50.5 billion, sale of KRW 29 million and net loss of KRW 13 billion. The transaction was resolved by the Board of Directors of Immunomic Therapeutics, Inc. The transaction is expected to close on September 15, 2021. Shinhan Accounting Firm acted as the external external evaluation agency in the transaction.
exax Inc. (KOSDAQ:A060230) completed the acquisition of an additional 7.32% stake in Immunomic Therapeutics, Inc. from Wise Alliance Co.,Ltd., Benoholdings, Inc. (KOSDAQ:A206400), Bellum 1 Fund and Ji-Man Park on September 3, 2021.
Beno TNR Inc, formerly BenoHoldings Inc, is a Korea-based company engaged in the construction business. The Company engages in the development, design, and construction of awning systems and radiant heating and cooling systems in the interior construction industry.
Exax Inc. completed the acquisition of an additional 7.32% stake in Immunomic Therapeutics, Inc. from Wise Alliance Co.,Ltd., Benoholdings, Inc., Bellum 1 Fund and Ji-Man Park.